Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Conditions

• Rheumatoid Arthritis

Interventions

• BIOLOGICAL: Certolizumab Pegol (CZP)
• BIOLOGICAL: Adalimumab (ADA)
• DRUG: Methotrexate (MTX)

Sponsor

UCB Pharma SA

Collaborators

• [object Object]